ARTICLE | Clinical News

Genfit preclinical data

February 24, 2014 8:00 AM UTC

In vitro, GFT505 blocked proliferation of cancer cells in the majority of 21 human cancer cell lines. The cell lines originated from myeloproliferative disorders and meningiomas, leukemia, gastrointestinal, lung, pancreatic, skin, colon, breast, thyroid and prostate cancers. Genfit could not be reached for next steps for GFT505 in cancer. ...